TB or not TB? - Rifater® may be the answer
Tuberculosis is once again top of the list of killer infectious diseases in adults throughout the world. Of particular concern is the rise in the incidence of multidrug-resistant strains of Mycobacterium tuberculosis
One approach to reducing the development of multidrug-resistant TB may lie in improving patient compliance. In answer to this, Marion Merrell Dow has recently launched Rifater® in the US, the only triple combination therapy for the treatment of active TB.